Objectives: To assess the prevalence and genotypes of Ambler class A extended-spectrum b-lactamases (ESBLs) in Korea.
Introduction
Escherichia coli and Klebsiella pneumoniae are the most frequent bacteria that produce SHV-and TEM-type extended-spectrum b-lactamases (ESBLs) and SHV-2a, SHV-12 and TME-52 are common in Korea.
1 CTX-M-type ESBLs, the most widely spread enzymes among non-TEM and non-SHV plasmid-mediated ESBLs, were initially reported in the late 1980s in Europe. 2 At present, the CTX-M family comprises more than 40 enzymes that have similar substrate specificities and inhibitor profiles to TEM and SHV derivatives but show greater hydrolytic activity against cefotaxime than ceftazidime. In Korea, CTX-M-3-, CTX-M-14-and CTX-M-15-producing E. coli and K. pneumoniae were reported in a survey of 13 Korean hospitals in 2002. 3 GES-type ESBLs are within the Ambler class A but have different substrate specificity. GES-1, which was detected in K. pneumoniae in French Guiana, had activity against cefoxitin, whereas GES-2 from Pseudomonas aeruginosa in South Africa was active against imipenem. 4 Recently, a few derivatives of GES-type ESBLs have been isolated in Greece and Japan. 5, 6 The aim of the present study was to describe the prevalence and shift of the ESBLs including non-TEM or -SHV ESBLs in E. coli and K. pneumoniae in recent years in Korea.
Methods

Bacterial strains
Consecutive non-duplicate nosocomial isolates of E. coli (n = 246) and K. pneumoniae (n = 239) were collected during February-July (Figure 1 ). E. coli J53 Azide R was used as the recipient strain for conjugation. E. coli ATCC 25933 was used as the reference strain for antimicrobial susceptibility testing.
Antimicrobial susceptibility tests and b-lactam resistance transfer assays
Antimicrobial susceptibilities were determined by disc diffusion and agar dilution methods according to the recommendations of the NCCLS.
7,8 ESBL production was detected by the double-disc synergy (DDS) method. Mating experiments were performed as described previously. 1 Transconjugants were selected on MacConkey agar supplemented with ceftazidime (2 mg/L) and sodium azide (150 mg/L; Sigma, St Louis, MO, USA).
Isoelectric focusing
Crude bacterial extracts from clinical isolates were prepared as described previously.
1 Sonic extracts and sample buffer (TEFCO corporation, Tokyo, Japan) were mixed in equal amounts and separated by electrophoresis on precast polyacrylamide gels (pH 3-10, TEFCO corporation, Tokyo, Japan) for 1 h at 100 V, 1 h at 200 V and 40 min at 300 V. b-Lactamase activity was detected with 0.5 mM nitrocefin (Oxoid, Basingstoke, UK).
Molecular analysis
Primers used in this study are listed in Table 1 . The templates for PCR amplification in clinical isolates were a whole-cell lysate or a plasmid preparation. The PCR products were then subjected to direct sequencing. Both strands of each PCR product were sequenced twice with an automatic sequencer (model 373A; Applied Biosystems, Weiterstadt, Germany).
Results
In the study period, clinical isolates of E. coli (n = 246) and K. pneumoniae (n = 239) were obtained from outpatients (43.1 and 23.0%, respectively), inpatients of general wards (46.3 and 60.7%, respectively) and inpatients of intensive care units (ICUs) (10.6 and 16.3%, respectively). They were from urine (52.6%), wound (18.2%), sputum (17.1%), blood (8.2%) and body fluid (3.9%). ESBL production was detected in 9.3% (23/246) of E. coli and 23.0% (55/239) of K. pneumoniae by the DDS test. DDS-positive isolates were found in all 12 hospitals (Figure 1) . The greatest numbers of ESBL-producing isolates were found in a hospital in Suwon city (E. coli, 5/20; K. pneumoniae, 9/20). The DDS-positive rates were higher in isolates from ICUs (E. coli, 23.1%; K. pneumoniae, 35.9%) than from outpatients or inpatients of general wards (E. coli, 0.9% and 14.0%; K. pneumoniae, 0.9% and 24.8%, respectively). Transfer of ceftazidime resistance to the E. coli J53 Azide R recipient by conjugation was successful for only 11 of 23 DDS-positive E. coli and 33 of 55 DDS-positive K. pneumoniae isolates.
Among 23 and 55 DDS-positive E. coli and K. pneumoniae isolates, genes encoding TEM-type b-lactamases were detected in 78.3% (18/23) of E. coli and 60% (33/55) of K. pneumoniae. Most of them were TEM-1 except for one isolate each of E. coli and K. pneumoniae that had TEM-52. The most common types of class A ESBLs identified were SHV-12 and CTX-M-3 in K. pneumoniae, and CTX-M-15 and CTX-M-3 in E. coli. GES-3, which was detected for the first time in Korea, was detected in two isolates of K. pneumoniae from Bundang city. Six isolates (12.2%) of K. pneumoniae and one E. coli carried multiple ESBL genes ( Table 2) . Non-TEM-and non-SHV-type ESBLs including PER-1, VEB, IBC and TLA-type ESBLs and members of CTX-M-2 and -8 groups were not detected in this survey. For 14 of 23 (60.9%) DDS-positive E. coli and six of 55 (10.9%) DDS-positive K. pneumoniae isolates no ESBL was detected. These isolates may have produced another ESBL, which was not determined in this study or might have given positive results for ESBL activity.
All of the 31 isolates producing SHV-12 were resistant to ceftazidime (MIC ‡ 64 mg/L). Five isolates producing both SHV-12 and CTX-M-type ESBLs were highly resistant to both ceftazidime and cefotaxime (both MICs ‡ 256 mg/L). Four isolates producing only CTX-M-14 had more than fourfold higher MICs for cefotaxime than for ceftazidime, but the isolates producing CTX-M-15 had similar levels of MICs for these drugs except one. Two isolates producing both GES-3 and SHV-12 had higher MICs for ceftazidime ( ‡256 mg/L) than for cefotaxime (64 mg/L). In isoelectric focusing studies, each of SHV-5, SHV-12, TEM-52, CTX-M-3, CTX-M-14, CTX-M-15 and GES-3 enzymes had corresponding pIs at 7.6, 8. 
Discussion
Compared with a survey in 1997, 9 the prevalence of ESBLproducing E. coli and K. pneumoniae has increased from 4.8 to 9.3% and 22 to 23%, respectively, in Korea. Past reports showed that the most common ESBL in Korea was TEM-52, 9 but it was detected in only one isolate each of E. coli and K. pneumoniae in this study. In 1998, about 70% (27/39) of K. pneumoniae isolates that produced SHV-type ESBLs were SHV-12, which confers higher levels of resistance against ceftazidime than SHV-2a and SHV-5, and the remaining 30% carried SHV-2a. 10 However, 86% (31/36) of SHV-type ESBLs were SHV-12 and only 8% (n = 3) and 6% (n = 2) were SHV-2a and SHV-5, respectively in this study.
We have previously shown that only 1.7% (9/520) of clinical E. coli and K. pneumoniae isolates produced CTX-M-type ESBLs in 2002, 3 but the prevalence of these enzymes was increased to 4.4% (26/585) in the present study. CTX-M-3 was the most common enzyme among CTX-M-type ESBLs, and was isolated from five hospitals (Figure 1 ). CTX-M-15 differs from CTX-M-3 by one amino acid substitution from glycine to aspartate at position 240, and this amino acid change results in increased enzymatic activity against ceftazidime. 2 It was also observed in this study that MICs of ceftazidime for four isolates of E. coli that produced CTX-M-15 were all ‡128 mg/L, which was higher than that of isolates producing other CTX-M-type ESBLs. Another noteworthy finding was that five CTX-M-type ESBL-producing isolates also produced SHV-12, simultaneously, and they were highly resistant to both ceftazidime and cefotaxime. Simultaneous production of both cefotaximase and ceftazidimase may confer a higher level of resistance against these oxyimino-cephalosporins in clinical isolates.
GES-3 was originally found in an E. coli isolate from a hospital in Greece. 5 GES-type ESBLs have not been reported before in Korea. However, in the present study, we found that two isolates of K. pneumoniae from a hospital in Bundang city produced both GES-3 and SHV-12 ESBLs. The MIC of ceftazidime (MIC ‡ 256 mg/L) was more than fourfold higher than that of cefotaxime (MIC 64 mg/L) in both of these isolates, and showed little change when clavulanic acid was added.
The present data suggest that the incidence of isolation of SHV-12 and CTX-M-type ESBLs has increased in E. coli and K. pneumoniae isolates in Korea. In conclusion, 9.3% of E. coli and 23.0% of K. pneumoniae isolates from Korea have produced Ambler class A ESBLs. The most common ESBLs in E. coli isolates were CTX-M-15 and CTX-M-3, and in K. pneumoniae were SHV-12 and CTX-M-3. In addition, a GES-type ESBL has emerged in Korea. 
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